InvestSMART

Racura Oncology Ltd (ASX: RAC) - Announcements

Current share price for RAC : $1.995 0.015 (0.75%)+

ASX company news and announcements for Racura Oncology Ltd (RAC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Racura Oncology Ltd (RAC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Racura Oncology Ltd (RAC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Racura Oncology Ltd (RAC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$391 Date of AGM & Closing Date for Director Nominations 6 Oct 2025 8:39AM $3.960 $1.995 fallen by 49.62%
$391 Application for quotation of securities - RAC 2 Oct 2025 2:47PM $4.400 $1.995 fallen by 54.66%
$391 Discovery of the Anticancer Mechanism of (EE)-bisantrene 2 Oct 2025 8:24AM $3.110 $1.995 fallen by 35.85%
$391 Application for quotation of securities - RAC 25 Sep 2025 2:42PM $3.100 $1.995 fallen by 35.65%
$391 RC220 IND Approval from Korean MFDS 24 Sep 2025 8:58AM $3.000 $1.995 fallen by 33.50%
$391 Trading Policy Update 23 Sep 2025 4:37PM $3.000 $1.995 fallen by 33.50%
$391 Race Oncology investor briefing presentation 18 Sep 2025 5:58PM $2.570 $1.995 fallen by 22.37%
$391 Application for quotation of securities - RAC 18 Sep 2025 3:50PM $2.560 $1.995 fallen by 22.07%
$391 Race Oncology Investor Webinar Invitation 18 Sep 2025 8:28AM $2.580 $1.995 fallen by 22.67%
$391 Hong Kong Investor Lunch Briefing Details 17 Sep 2025 8:51AM $2.300 $1.995 fallen by 13.26%
$391 Race Breakthrough Composition of Matter IP Discovery 16 Sep 2025 8:59AM $1.800 $1.995 risen by 10.83%
$391 Application for quotation of securities - RAC 11 Sep 2025 2:35PM $1.510 $1.995 risen by 32.12%
$391 Application for quotation of securities - RAC 2 Sep 2025 1:55PM $1.220 $1.995 risen by 63.52%
$391 First Hong Kong Site Activated for RC220 Trial 2 Sep 2025 9:21AM $1.255 $1.995 risen by 58.96%
$391 First Hong Kong Site Activated for RC220 Trial 2 Sep 2025 9:21AM $1.255 $1.995 risen by 58.96%
$391 Appendix 4G 26 Aug 2025 4:48PM $1.200 $1.995 risen by 66.25%
$391 Corporate Governance Statement 26 Aug 2025 4:47PM $1.200 $1.995 risen by 66.25%
$391 Appendix 4E & Annual Report 26 Aug 2025 4:45PM $1.200 $1.995 risen by 66.25%
$391 Phase 2 Bisantrene AML Trial Results Published 4 Aug 2025 1:57PM $1.155 $1.995 risen by 72.73%
$391 Notification regarding unquoted securities - RAC 24 Jul 2025 4:34PM $1.185 $1.995 risen by 68.35%
$391 June 2025 Quarterly Activity Report and Appendix 4C 23 Jul 2025 8:28AM $1.140 $1.995 risen by 75%
$391 Race Oncology Upcoming 2025 Investor Events 15 Jul 2025 1:29PM $1.155 $1.995 risen by 72.73%
$391 RC220 Human Ethics Approvals Received in Hong Kong 10 Jul 2025 9:07AM $1.170 $1.995 risen by 70.51%
$391 Application for quotation of securities - RAC 26 Jun 2025 1:49PM $1.240 $1.995 risen by 60.89%
$391 Application for quotation of securities - RAC 19 Jun 2025 2:35PM $1.355 $1.995 risen by 47.23%

126 - 150 of 988 results

Page 6 of 40

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.